Table 2.
Baseline clinicopathological characteristics of the PECS II block and no-block groups.
| Block (n = 28) | No Block (n = 27) | p-Value | |
|---|---|---|---|
| Age (years) | 43.8 ± 11.7 (range, 24–64) |
39.0 ± 12.8 (range, 18–69) |
0.157 |
| Female | 28 (100%) | 24 (88.9%) | 0.111 |
| Extent of operation | 0.206 | ||
| Lobectomy | 26 (92.9%) | 22 (81.5%) | |
| Total thyroidectomy | 2 (7.1%) | 22 (18.5%) | |
| Pathology | 0.648 | ||
| PTC | 23 (82.1%) | 22 (81.5%) | |
| HCC | 0 | 1 (3.7%) | |
| NIFTP | 2 (7.1%) | 1 (3.7%) | |
| Follicular adenoma | 2 (7.1%) | 2 (7.4%) | |
| Graves’ disease | 1 (3.6%) | 0 | |
| Parathyroid adenoma | 0 | 1 (3.7%) | |
| Tumor size (cm) | 0.9 ± 0.6 | 1.3 ± 1.2 | 0.160 |
| Multiplicity | 11/25 (44.0%) | 8/24 (33.3%) | 0.444 |
| Minimal ETE | 16/25 (64.0%) | 14/24 (58.3%) | 0.684 |
| Thyroiditis | 14 (50.0%) | 11 (40.7%) | 0.491 |
| Harvested LNs | 6.4 ± 3.1 | 5.9 ± 4.0 | 0.651 |
| Positive LNs | 1.0 ± 1.8 | 1.0 ± 1.6 | 1.000 |
| T stage | 0.352 | ||
| T1 | 23 (100%) | 21 (91.3%) | |
| T2 | 0 | 1 (3.7%) | |
| T3a | 0 | 1 (3.7%) | |
| N stage | 0.546 | ||
| N0 | 15 (65.2%) | 13 (56.5%) | |
| N1a | 8 (34.80%) | 10 (43.5%) | |
| TNM stage | 1.000 | ||
| Stage I | 22 (95.7%) | 22 (95.7%) | |
| Stage II | 1 (4.3%) | 1 (4.3%) |
Data are expressed as the patient number (%) or mean ± standard deviation. A statistically significant difference was defined as p < 0.05. Abbreviations: PTC, papillary thyroid carcinoma; HCC, Hurthle cell carcinoma; NIFTP, noninvasive follicular thyroid neoplasm with papillary-like nuclear features; ETE, extrathyroidal extension; LN, lymph node; T, tumor; N, node; M, metastasis.